BCL2 and lung carcinoma: Further studies showed that 24–48 h treatment of EVO at 20–40 μM significant inhibited cell growth and increased apoptosis with the activation of caspases-9, -3, and -8 and DR5 and the alteration of the ratio of Bax/Bcl-2 in human lung cancer A549 and H1299 cells (Mohan et al., 2016).